

**CLEARBRIDGE HEALTH LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 201001436C)

---

**UPDATE ON CIVIL SUIT FILED BY A JOINT VENTURE PARTNER OF AN INDIRECT  
SUBSIDIARY IN INDONESIA**

---

The Board of Directors of Clearbridge Health Limited (the "**Company**") and together with its subsidiaries, the "**Group**") refers to the announcements dated 31 May 2020, 23 August 2020, 8 June 2021, and 6 August 2021 (collectively, the "**Announcements**") relating to the civil suit (the "**Suit**") filed by PT Tirta Medika Nusantara ("**TMN**"), an existing shareholder of the Company's indirect subsidiary, PT Tirta Medika Jaya ("**TMJ**"), against, among others, (1) Clearbridge Medical Asia Pte. Ltd., a wholly-owned subsidiary of the Company ("**CBMA**"), and (2) TMJ. Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcements.

The Group wishes to announce that through a notice from the North Jakarta District Court dated 3 August 2022 in relation to the Suit, the Jakarta High Court gave judgment in favour of TMN for the reasons that it has proven that the North Jakarta District Court had in fact jurisdiction to hear the Suit. In this regard, the Jakarta High Court has ordered that the Suit be returned to and heard in the North Jakarta District Court (the "**Court's Decision**").

The Group is currently seeking legal advice on this matter and will update shareholders and potential investors of the Company on any further development on the matters by way of a further announcement(s) as and when necessary in accordance with the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalist.

Presently, the operations at TMJ and CBMA are unaffected by the Suit and the Court's Decision.

Moving forward, the Suit and the Court's Decision will have no material impact on the financial performance and condition of the Group for the current financial year ending 31 December 2022 ("**FY2022**") in the event that the Suit (and any subsequent appeals by TMN) is decided, in FY2022, in favour of CBMA and/or TMJ.

By contrast, the Suit and the Court's Decision may have a material adverse impact on the financial performance and condition of the Group for FY2022 in the event that the Suit (and any subsequent appeals by CBMA and/or TMJ) is decided, in FY2022, in favour of TMN. As set out in the Company's announcement on 31 May 2020, TMN is seeking, among others, (a) the Court's declaration that a certain notarial deed has been made unlawfully and consequently, (b) damages of IDR 1.06 trillion (approximately SGD 102 million) to be paid. No substantiation has been provided by TMN on how this claim for IDR 1.06 trillion has been derived.

The Group is unable to comment further on the probability of the outcome of the Suit at this juncture. The Group and its legal advisors will update its shareholders if there are any further material developments on this matter.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

**BY ORDER OF THE BOARD**

YEE PINH JEREMY

Executive Director and Chief Executive Officer

4 August 2022

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*